Infiltrating neutrophils promote renal cell carcinoma progression  via VEGFa/HIF2α and estrogen receptor β signals

Wenbin Song; Chiuan-Ren Yeh; Dalin He; Yong Wang; Hongjun Xie; See-Tong Pang; Luke Sien-Shih Chang; Lei Li; Shuyuan Yeh

doi:10.18632/oncotarget.4478

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Infiltrating neutrophils promote renal cell carcinoma progression via VEGFa/HIF2α and estrogen receptor β signals

Wenbin Song _, Chiuan-Ren Yeh, Dalin He, Yong Wang, Hongjun Xie, See-Tong Pang, Luke Sien-Shih Chang, Lei Li and Shuyuan Yeh

PDF | HTML | How to cite

Oncotarget. 2015; 6:19290-19304. https://doi.org/10.18632/oncotarget.4478

Metrics: PDF 1806 views | HTML 2458 views | ?

Abstract

Wenbin Song1,2,*, Chiuan-Ren Yeh1,*, Dalin He2,*, Yong Wang1, Hongjun Xie1,2, See-Tong Pang1, Luke Sien-Shih Chang2, Lei Li2 and Shuyuan Yeh1

1 George Whipple Lab for Cancer Research, Departments of Urology and Pathology, University of Rochester Medical Center, Rochester, New York, USA

2 Sex Hormone Research Center, Department of Urology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

* These authors Contributed equally to this work

Correspondence to:

Lei Li, email:

Shuyuan Yeh, email:

Keywords: tumor microenvironment, RCC, Neutrophils, ERβ, VEGFa and HIF pathways

Received: November 24, 2014 Accepted: April 02, 2015 Published: June 15, 2015

Abstract

Neutrophils make up a significant portion of the infiltrated immune cells found in the tumor microenvironment. Here we found more infiltrated neutrophils in human renal cell carcinoma (RCC) lesions than adjacent benign areas. In vitro RCC studies showed that neutrophils (HL-60N cells) infiltrated toward RCC cells and subsequently enhanced RCC cell migration and invasion. Co-culture of RCC cells with HL-60N cells up-regulated ERβ, VEGFa and HIF2α mRNA levels. ERβ signals increased RCC cell migration via induction of the VEGFa/HIF2α pathway. Treatment of HIF inhibitor or rapamycin, or knockdown of ERβ in RCC cells reversed HL-60N-promoted RCC migration. In vivo data using orthotopically xenografted RCC mouse model confirmed that infiltrated neutrophils promoted RCC migration via modulating the expressions of ERβ, VEGFa and HIF2α signal pathways. Together, our studies revealed that neutrophils are favorably recruited to the RCC cells to promote the RCC migration and invasion. Targeting the infiltrating RCC tumor microenvironment with anti-estrogen or rapamycin may be a potential therapy to suppress RCC progression.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4478

Publication Alerts

Research Papers:

Infiltrating neutrophils promote renal cell carcinoma progression via VEGFa/HIF2α and estrogen receptor β signals

Abstract